Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Nkarta, Inc. (NKTX)

Nkarta Q3 2026 net loss widens to $33.3 million, or $0.45 per share

Negative Impact 3 of 5 earnings Written later

Nkarta reported third-quarter 2026 results, with a net loss of $33.3 million, or $0.45 per share, compared with a net loss of $21.7 million, or $0.29 per share, a year earlier. The company said its $216.0 million in cash, cash equivalents, restricted cash and investments as of September 30, 2026, is expected to fund operations into 2029. Higher research and development spending drove the larger loss, and shareholders face continued losses while the company's lead candidate is still in clinical trials.

Key points

  • Q3 2026 net loss of $33.3 million ($0.45 per share), up from $21.7 million ($0.29 per share) in Q3 2025
  • R&D expenses rose to $29.5 million from $20.2 million; G&A expenses fell to $6.3 million from $7.1 million
  • Cash and investments were $216.0 million on September 30, 2026, down from $295.1 million on December 31, 2025
  • Initial NKX019 clinical data to be presented at ACR Convergence 2026, with an oral presentation on November 8

The filing

CompanyNkarta, Inc. (NKTX)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:36 PM ET
Accession number0001787400-26-000020

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.